Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Provided By GlobeNewswire
Last update: Sep 3, 2025
RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and small molecule therapies for other ophthalmic disorders, announced today that George Magrath, MD, Chief Executive Officer, and Ash Jayagopal, Ph.D., MBA, Chief Scientific and Development Officer, will deliver a corporate update at the H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025. The presentation will be available on demand on Monday, September 8, 2025 at 7:00 a.m. ET.
Read more at globenewswire.com
